Company intelligence / Profile preview

Fount Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Fount Therapeutics was an early-stage biotechnology company focused on the biology of nutrient sensing and the mTOR pathway to develop treatments for cancer and other diseases. Co-founded by prominent researchers in the field of metabolism, the company aimed to leverage insights into how cells sense and respond to nutrients. Its research primarily targeted the mTORC1 and mTORC2 complexes to modulate cellular growth and metabolism. While it attracted significant early-stage investment from firms like GV and Casdin Capital, the company operated largely in stealth mode. Following controversies involving its scientific leadership, the company is no longer active.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Fount Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fount Therapeutics.

Explore the full profile